GE HealthCare had its first patient scanned in a phase I clinical trial for an investigational F-18 CD8-targeted PET imaging radiopharmaceutical.
The trial aims to use the radiopharmaceutical to find out if patients have CD8+ T cells in their tumors and perhaps be more likely to respond to immune checkpoint inhibitors. The study will also then help identify early response to immunotherapies, using sequential whole-body imaging to monitor CD8 changes over time.
GE said the F-18 CD8 PET radiopharmaceutical is intended for same-day and subsequent sequential imaging.
![A 53-year-old patient (patient number four) with a recurrent pituitary adenoma with extension of a cystic component of disease to the medial temporal lobe apparent on MRI (contoured in blue), and extension of disease to the left sphenoid bone and orbital apex apparent on [68Ga]Ga-DOTA-TATE (contoured in yellow).](https://img.auntminnie.com/mindful/smg/workspaces/default/uploads/2026/04/pituitary-tumor.QGsEnyB4bU.jpg?auto=format%2Ccompress&dpr=2&fit=crop&h=167&q=70&w=250)
